SCHEMBL3372051

SCHEMBL3372051

COc1cccc(-c2nc(N)c(C#N)c(-c3ccc(Cl)cc3Cl)n2)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 10/20 0.70
GSK3A P49840 1/20 0.54
GSK3B P49841 1/20 0.54
DYRK1A Q13627 1/20 0.54
CLK4 Q9HAZ1 1/20 0.54
ADORA1 P30542 3/20 0.49
ADORA2A P29274 2/20 0.49
ADORA2B P29275 1/20 0.49
KDM4E B2RXH2 2/20 0.48
RXFP1 Q9HBX9 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48
GLA P06280 1/20 0.48
CYP3A4 P08684 1/20 0.47
HPGD P15428 2/20 0.47
MEN1 O00255 1/20 0.47
ALDH1A1 P00352 1/20 0.47
POLB P06746 1/20 0.47
KMT2A Q03164 1/20 0.47
TP53 P04637 1/20 0.47
HTT P42858 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3368098 0.86 DPP4 (0.68) DPP4GSK3AGSK3BDYRK1ACLK4
SCHEMBL3372730 0.84 DPP4 (0.65) DPP4GSK3AGSK3BDYRK1ACLK4
SCHEMBL3372610 0.82 GSK3A (0.55) DPP4GSK3AGSK3BDYRK1ACLK4
SCHEMBL3370949 0.82 DPP4 (1.00) DPP4CYP3A4
SCHEMBL6871446 0.80 DPP4 (0.66) DPP4GSK3AGSK3BDYRK1ACLK4
SCHEMBL3369169 0.80 ADORA1 (0.71) DPP4ADORA1ADORA2AADORA2BKDM4E
SCHEMBL6871445 0.77 DPP4 (0.67) DPP4GSK3AGSK3BDYRK1ACLK4
SCHEMBL15298377 0.76 ADORA1 (0.61) ADORA1ADORA2AADORA2BKDM4ERXFP1
SCHEMBL15286427 0.75 ADORA1 (0.67) ADORA1ADORA2AADORA2BKDM4ERXFP1
SCHEMBL5744860 0.74 ADORA1 (0.60) DPP4ADORA1ADORA2AADORA2BKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1476435-B1 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-06-30 EP disclosed
US-7022718-B2 Pyridine and pyrimidine derivatives HOFFMANN-LA ROCHE INC. (US) 2006-04-04 US disclosed
US-20050143405-A1 Pyridine and pyrimidine derivatives BOEHRINGER MARKUS (CH) 2005-06-30 US disclosed
US-6867205-B2 Pyridine and pyrimidine derivatives HOFFMAN-LA ROCHE INC. (US) 2005-03-15 US disclosed
EP-1476435-A1 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-11-17 EP disclosed
WO-2003068757-A9 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES HOFFMANN LA ROCHE (CH) 2004-10-07 WO disclosed
US-20030216382-A1 Pyridine and pyrimidine derivatives HOFFMAN-LA ROCHE INC. 2003-11-20 US disclosed
WO-2003068757-A1 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216382-A1 Pyridine and pyrimidine derivatives DPP4, GPR119, G6PC1 DPP4 1/4885GSK3A 2021/4885GSK3B 1969/4885
US-20050143405-A1 Pyridine and pyrimidine derivatives DPP4, GPR119, PDXK DPP4 1/4885GSK3A 2252/4885GSK3B 2013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.